Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;15(8):457-72.
doi: 10.1038/nrc3973.

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Ignacio Melero  1 , David M Berman  2 , M Angela Aznar  1 , Alan J Korman  3 , José Luis Pérez Gracia  1 , John Haanen  4
Affiliations
Review

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Ignacio Melero et al. Nat Rev Cancer. 2015 Aug.

Abstract

Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.

PubMed Disclaimer

References

    1. Clin Cancer Res. 2011 Jun 15;17(12):4101-9 - PubMed
    1. J Immunol. 2006 Sep 1;177(5):2969-75 - PubMed
    1. Oncoimmunology. 2014 May 14;3:e28780 - PubMed
    1. Nature. 2006 Feb 9;439(7077):682-7 - PubMed
    1. Arch Immunol Ther Exp (Warsz). 2002;50(1):13-8 - PubMed

LinkOut - more resources